| AMERICAN DRUGS | ANATOMY | HEALTH TOPICS | HIV/AIDS GLOSSARY | DISEASES | HEALTH ARTICLES | GENOME | OCCUPATIONS |

Cortavance

Spanish Simplified Chinese French German Russian Hindi Arabic Portuguese
















Summary for the public


What is Cortavance?

Cortavance is a spray containing a solution of the active substance hydrocortisone aceponate.


What is Cortavance used for?

Cortavance is used to treat inflamed and itchy skin conditions in dogs. Cortavance is given once a day for 7 days. It is sprayed on the affected area, avoiding the eyes. The pump delivers in two sprays enough medicine to treat an area of about 100 cm2. If no improvement is seen after 7 days, the treatment should be re-evaluated by a veterinarian.


How does Cortavance work?

The active substance in Cortavance, hydrocortisone aceponate, is a steroid which is a type of substance that helps to reduce inflammation. The steroid is in a special chemical form (a diester) that makes it effective at low doses in skin conditions as the medicine is able to get into and remain longer in the outer layer of the skin.


How has Cortavance been studied?

The clinical part of the dossier consisted of studies to determine the dose and of one field trial. The field trial consisted of a multi-site study comparing treatment of dogs with itchy skin conditions with Cortavance to treatment with a different steroid-containing product. Fifty-four dogs were treated with Cortavance and 51 with this other product.


What benefit has Cortavance shown during the studies?

The studies to determine the dose generally supported the chosen dose and the length of treatment. Significant improvement of the skin condition was demonstrated in several studies under controlled conditions, whereas significant reduction of itching was demonstrated in only one of these laboratory studies in which the dogs received treatment against external parasites at the same time. Results from the field trial indicated comparable efficacy between Cortavance and the comparator product.


What is the risk associated with Cortavance?

There are no side effects reported in animals who have been treated with Cortavance. The treatment area should not normally exceed an area corresponding to the two flanks of the animal. Before treatment, any other existing skin conditions (such as an infection) must be treated and Cortavance should not be used on skin ulcers. The medicine should not normally be used in dogs suffering from Cushing’s syndrome (a disorder where the body produces too much natural steroid), and in young animals (under 7 months of age) as steroids are known to slow growth.


What are the precautions for the person who gives the medicine or comes into contact with the animal?

Wash hands after use. In case of accidental contact (skin, eye), wash thoroughly with water.

In case of accidental ingestion, seek medical advice immediately and show the leaflet or the label to the physician.

Spray preferably in a well ventilated area. The spray is flammable and should not be used next to a naked flame or any incandescent material. Do not smoke when applying this product.


Why has Cortavance been approved?

The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Cortavance exceed the risks for the treatment of inflamed and itchy skin conditions and recommended that Cortavance be given a marketing authorisation. The benefit-risk balance may be found in module 6 of this EPAR.


Other information about Cortavance

The European Commission granted a marketing authorisation valid throughout the European Union, for Cortavance to Virback S.A. on 09/01/2007. Information on the prescription status of this product may be found on the label/outer package.

Authorisation details
Name: Cortavance
EMEA Product number: EMEA/V/C/000110
Active substance: hydrocortisone aceponate
INN or common name: hydrocortisone
Species: Dogs
ATCvet Code: QD07AC
Marketing Authorisation Holder: Virbac S.A.
Revision: 2
Date of issue of Market Authorisation valid throughout the European Union: 09/01/2007
Contact address:
Virbac S.A.
1ère Avenue 2065 M
06516 Carros
France



Product Characteristics

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS


1.
NAME OF VETERINARY THE MEDICINAL PRODUCT
CORTAVANCE 0.584 mg/ml cutaneous spray solution for dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substance:
Hydrocortisone aceponate
0.584 mg/ml.
For a full list of excipients see section 6.1.
3.
PHARMACEUTICAL FORM
Cutaneous spray, solution.
4.
CLINICAL PARTICULARS
4.1 Target species
Dogs
4.2 Indications for use, specifying the target species
For symptomatic treatment of inflammatory and pruritic dermatoses in dogs.
4.3 Contraindications
Do not use on cutaneous ulcers.
4.4 Special warnings for each target species
Total body surface treated should not exceed a surface corresponding for example to a treatment of
two flanks from the spine to the mammary chains including the shoulders and the thighs. Otherwise,
use only according to the risk-benefit assessment and subject the dog to regular clinical evaluations.
4.5 Special precautions for use
Special precautions for use in animals
In the case of concurrent microbial disease or parasitic infestation, the dog should receive appropriate
treatment for such condition.
In the absence of specific information, the use in animal suffering from Cushing’s syndrome shall be
based on the risk-benefit assessment.
Since glucocorticosteroids are known to slow growth, use in young animals (under 7 months of age)
shall be based on the risk-benefit assessment and subject to regular clinical evaluations.
In 12 dogs suffering from atopic dermatitis, after topical application on the skin at the recommended
therapeutic dosage for 28 to 70 consecutive days, no noticeable effect on the systemic cortisol level
was observed.
2
Special precautions to be taken by the person administering the veterinary medicinal product to
animals
In case of accidental skin contact, it is recommended to wash thoroughly with water. Wash hands after
use.
Avoid contact with eyes. In case of accidental eye contact, rinse with abundant quantities of water. In
case of eye irritation, seek medical advice.
In case of accidental ingestion, seek medical advice immediately and show the leaflet or the label to
the physician.
Spray preferably in a well ventilated area.
Flammable.
Do not spray on naked flame or any incandescent material. Do not smoke while handling the
veterinary medicinal product.
The solvent in this product may stain certain materials including painted, varnished or other household
surfaces or furnishings. Allow the application site to dry before permitting contact with such materials.
4.6 Adverse reactions (frequency and seriousness)
None.
4.7 Use during pregnancy, lactation or lay
The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
Systemic absorption of hydrocortisone aceponate being negligible, it is unlikely for teratogenic,
foetotoxic, maternotoxic effects to happen at the recommended dosage in dogs.
Use only accordingly to the risk-benefit assessment by the responsible veterinarian.
4.8 Interaction with other medicinal products and other forms of interaction
In the absence of information, it is recommended not to apply other topical preparations
simultaneously on the same lesions.
4.9 Amounts to be administered and administration route
Cutaneous use.
Before administration, screw the pump spray on the bottle.
The veterinary medicinal product is then applied by activating the pump spray, from a distance of
about 10 cm of the area to be treated.
The recommended dosage is 1.52 µg of hydrocortisone aceponate/cm 2 of affected skin per day. This
dosage can be achieved with two pump spray activations over a surface to be treated equivalent to a
square of 10 cm x 10 cm. Repeat the treatment daily for 7 consecutive days.
Care should be taken to avoid spraying into the eyes of the animal.
Presented as a volatile spray, this veterinary medicinal product does not require any massage.
In case of conditions requiring an extended treatment, the responsible veterinarian should subject the
use of the veterinary medicinal product to the risk-benefit assessment.
If signs fail to improve within 7 days, treatment should be re-evaluated by the veterinarian.
3
4.10 Overdose (symptoms, emergency procedures, antidotes)
After topical application on the skin at the recommended therapeutic dosage and twice the
recommended duration of treatment and at up to a body surface corresponding to the two flanks, from
the spine to the mammary chains including the shoulder and the thighs, no systemic effects are
observed.
Tolerance studies using 3 and 5 times the recommended dosage for twice the recommended duration
of treatment resulted in a reduced capacity for production of cortisol that is fully reversible within 7 to
9 weeks after the end of treatment.
4.11 Withdrawalperiods
Not applicable.
5.
PHARMACOLOGICAL PROPERTIES
Pharmacotherapeutic group: Glucorticosteroids, dermatological preparations.
ATCvet code: QD07AC.
5.1 Pharmacodynamic properties
The veterinary medicinal product contains the active substance hydrocortisone aceponate.
Hydrocortisone aceponate (HCA) is a dermocorticoid with a potent intrinsic glucocorticoid activity
which means a relief of both inflammation and pruritus leading to a quick improvement of skin lesions
observed in case of inflammatory and pruritic dermatosis.
5.2 Pharmacokinetic particulars
HCA belongs to the diesters class of the glucocorticosteroids.
The diesters are lipophilic components ensuring an enhanced penetration into the skin associated to a
low plasma availability. HCA thus accumulates in the dog’s skin allowing local efficacy at low
dosage. The diesters are transformed inside the skin structures. This transformation is responsible for
the potency of the therapeutic class. In laboratory animals, hydrocortisone aceponate is eliminated the
same way as hydrocortisone (other name for endogenous cortisol) through urine and faeces.
Topical application of diesters results in high therapeutic index: high local activity with reduced
systemic secondary effects.
6.
PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Propylene glycol methyl ether.
6.2 Incompatibilities
None known.
6.3 Shelf life
Shelf-life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf-life after first opening the immediate packaging: 6 months.
4
6.4. Special precautions for storage
This veterinary medicinal product does not require any special storage conditions.
6.5 Nature and composition of immediate packaging
Box containing a polyethylene terephtalate (PET) bottle filled with 76 ml of solution, closed with an
aluminium screw cap or a white plastic screw cap and a pump spray.
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste
materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal
products should be disposed of in accordance with local requirements.
7.
MARKETING AUTHORISATION HOLDER
VIRBAC S.A.
1 ère avenue 2065 m L.I.D.
06516 Carros
FRANCE
0033/4.92.08.73.00
0033/4.92.08.73.48
dar@virbac.fr
8.
MARKETING AUTHORISATION NUMBER
EU/2/06/069/001
9.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
9 January 2007
10 DATE OF REVISION OF THE TEXT
02/07/2010
PROHIBITION OF SALE, SUPPLY AND/OR USE
Not applicable.
5
ANNEX II
A.
MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND
MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR
BATCH RELEASE
B.
CONDITIONS OR RESTRICTIONS OF THE MARKETING
AUTHORISATION REGARDING SUPPLY OR USE
C.
CONDITIONS OR RESTRICTIONS OF THE MARKETING
AUTHORISATION WITH REGARD TO SAFE AND EFFECTIVE USE
D.
STATEMENT OF THE MRLs
6
A. MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH
RELEASE
Name and address of the manufacturer(s) responsible for batch release
VIRBAC SA
1 ère Avenue - 2065 m – L.I.D
06516 Carros, France
B. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION
REGARDING SUPPLY OR USE
To be supplied only on veterinary prescription.
C. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH
REGARD TO THE SAFE AND EFFECTIVE USE OF THE PRODUCT
Not applicable.
D. STATEMENT OF THE MRLs
Not applicable.
7
ANNEX III
LABELLING AND PACKAGE LEAFLET
8
A. LABELLING
9
PARTICULARS TO APPEAR ON THE OUTER PACKAGE
Carton box
1.
NAME OF VETERINARY THE MEDICINAL PRODUCT
CORTAVANCE 0.584 mg/ml cutaneous spray solution for dogs.
2.
STATEMENT OF ACTIVE AND OTHER SUBSTANCES
Hydrocortisone aceponate
0.584 mg/ml.
Contains no preservative.
3.
PHARMACEUTICAL FORM
Cutaneous spray, solution.
4.
PACKAGE SIZE
Bottle containing 76 ml of solution.
5.
TARGET SPECIES
Dogs
6.
INDICATION(S)
For symptomatic treatment of inflammatory and pruritic dermatoses in dogs.
7.
METHOD AND ROUTE(S) OF ADMINISTRATION
Cutaneous use.
Read the package leaflet before use.
8.
WITHDRAWAL PERIOD
Not applicable.
10
 
9.
SPECIAL WARNING(S), IF NECESSARY
Total body surface treated should not exceed a surface corresponding for example to a treatment of
two flanks from the spine to the mammary chains including the shoulders and the thighs. Otherwise,
use only according to the risk-benefit assessment by the responsible veterinarian and subject the dog to
regular clinical evaluations.
10. EXPIRY DATE
EXP {MM/AA/AA}
Once opened, use by 6 months.
11. SPECIAL STORAGE CONDITIONS
This veterinary medicinal product does not require any special storage conditions.
12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR
WASTE MATERIALS, IF ANY
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal
products should be disposed of in accordance with local requirements.
13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE, if applicable
For animal treatment only - to be supplied only on veterinary prescription.
14. THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”
Keep out of the reach and sight of children.
15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
VIRBAC S.A.
1 ère avenue 2065 m L.I.D.
06516 Carros
FRANCE
16. MARKETING AUTHORISATION NUMBER(S)
EU/2/06/069/001
17. MANUFACTURER’S BATCH NUMBER
Batch {number}
11
 
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE
Bottle
1.
NAME OF VETERINARY THE MEDICINAL PRODUCT
CORTAVANCE 0.584 mg/ml cutaneous spray solution for dogs
2.
STATEMENT OF ACTIVE AND OTHER SUBSTANCES
Hydrocortisone aceponate
0.584 mg/ml.
Contains no preservative.
3.
PHARMACEUTICAL FORM
Cutaneous spray, solution.
4.
PACKAGE SIZE
Bottle containing 76 ml of solution.
5.
TARGET SPECIES
Dogs
6.
INDICATION(S)
For symptomatic treatment of inflammatory and pruritic dermatoses in dogs.
7.
METHOD AND ROUTE(S) OF ADMINISTRATION
Cutaneous use.
Read the package leaflet before use.
8.
WITHDRAWAL PERIOD
Not applicable.
12
 
9.
SPECIAL WARNING(S), IF NECESSARY
Total body surface treated should not exceed a surface corresponding for example to a treatment of
two flanks from the spine to the mammary chains including the shoulders and the thighs. Otherwise,
use only according to the risk-benefit assessment by the responsible veterinarian and subject the dog to
regular clinical evaluations.
10. EXPIRY DATE
EXP {MM/AA/AA}
Once opened, use by 6 months.
11. SPECIAL STORAGE CONDITIONS
This veterinary medicinal product does not require any special storage conditions.
12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR
WASTE MATERIALS, IF ANY
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal
products should be disposed of in accordance with local requirements.
13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE, if applicable
For animal treatment only - to be supplied only on veterinary prescription.
14. THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”
Keep out of the reach and sight of children.
15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
VIRBAC S.A.
1 ère avenue 2065 m L.I.D.
06516 Carros
FRANCE
16. MARKETING AUTHORISATION NUMBER(S)
EU/2/06/069/001
17. MANUFACTURER’S BATCH NUMBER
Batch {number}
13
 
B. PACKAGE LEAFLET
14
PACKAGE LEAFLET
CORTAVANCE 0.584 mg/ml cutaneous spray solution for dogs
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Marketing authorisation holder and manufacturer:
VIRBAC S.A.
1 ère avenue 2065 m L.I.D
06516 Carros
FRANCE
2.
NAME OF VETERINARY THE MEDICINAL PRODUCT
CORTAVANCE 0.584 mg/ml cutaneous spray solution for dogs
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Hydrocortisone aceponate
0.584 mg/ml.
Contains no preservative.
4.
INDICATIONS
For symptomatic treatment of inflammatory and pruritic dermatoses in dogs.
5.
CONTRAINDICATIONS
Do not use on cutaneous ulcers.
6.
ADVERSE REACTIONS
None known.
If you notice any serious effects or other effects not mentioned in this leaflet, please inform you
veterinary surgeon.
7.
TARGET SPECIES
Dogs
8.
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
Cutaneous use.
Before administration, screw the pump spray on the bottle.
15
The veterinary medicinal product is then applied by activating the pump spray, from a distance of
about 10 cm of the area to be treated.
The recommended dosage is 1.52 µg of hydrocortisone aceponate/cm 2 of affected skin per day. This
dosage can be achieved with two pump spray activations over a surface to be treated equivalent to a
square of 10 cm x 10 cm. Repeat the treatment daily for 7 consecutive days.
Care should be taken to avoid spraying into the eyes of the animal.
Presented as a volatile spray, this veterinary medicinal product does not require any massage.
In case of conditions requiring an extended treatment, the responsible veterinarian should subject the
use of the product to the risk-benefit assessment by the responsible veterinarian.
If signs fail to improve within 7 days, treatment should be re-evaluated by the veterinarian
9.
ADVICE ON CORRECT ADMINISTRATION
Spray preferably in a well ventilated area.
Flammable.
Do not spray on naked flame or any incandescent material. Do not smoke while handling the product.
10. WITHDRAWAL PERIOD
Not applicable.
11. SPECIAL STORAGE PRECAUTIONS
Keep out of the reach and sight of children.
This veterinary medicinal product does not require any special storage conditions.
Do not use after the expiry date stated on the label.
Shelf-life after first opening the container: 6 months.
12. SPECIAL WARNING(S)
Special precautions for use in animals
In the case of concurrent microbial disease or parasitic infestation, the dog should receive appropriate
treatment for such condition.
In the absence of specific information, the use in animal suffering from Cushing’s syndrome shall be
based on the risk-benefit assessment.
Since glucocorticosteroids are known to slow growth, use in young animals (under 7 months of age)
shall be based on the risk-benefit assessment and subject to regular clinical evaluations.
In 12 dogs suffering from atopic dermatitis, after topical application on the skin at the recommended
therapeutic dosage for 28 to 70 consecutive days, no noticeable effect on the systemic cortisol level
was observed.
Total body surface treated should not exceed a surface corresponding for example to a treatment of
two flanks from the spine to the mammary chains including the shoulders and the thighs. Otherwise,
use only according to the risk-benefit assessment and subject the dog to regular clinical evaluations
16
The safety of the veterinary medicinal product has not been established during pregnancy and
lactation. Systemic absorption of hydrocortisone aceponate being negligible, it is unlikely for
teratogenic, foetotoxic, maternotoxic effects to happen at the recommended dosage in dogs.
Use only accordingly to the risk-benefit assessment by the responsible veterinarian.
Special precautions to be taken by the person administering the veterinary medicinal product to
animals
In case of accidental skin contact, it is recommended to wash thoroughly with water. Wash hands after
use.
Avoid contact with eyes. In case of accidental eye contact, rinse with abundant quantities of water. In
case of eye irritation, seek medical advice.
In case of accidental ingestion, seek medical advice immediately and show the leaflet or the label to
the physician.
In the absence of information, it is recommended not to apply other topical preparations
simultaneously on the same lesions.
The solvent in this product may stain certain materials including painted, varnished or other household
surfaces or furnishings. Allow the application site to dry before permitting contact with such materials.
13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE
MATERIALS, IF ANY
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal
products should be disposed of in accordance with local requirements.
14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED
02/07/2010
15. OTHER INFORMATION
Hydrocortisone aceponate (HCA) administered topically accumulates and is metabolised in skin, as
suggested by radioactivity distribution studies and pharmacokinetic data. This results in minimal
amounts to reach the blood stream. This particularity will increase the ratio between the desired local
anti-inflammatory effect in the skin and the undesirable systemic effects.
HCA applications on the skin lesions provide rapid reduction of the skin redness, irritation and
scratching while minimising the general effects.
After topical application on the skin at the recommended therapeutic dosage and twice the
recommended duration of treatment and at up to a body surface corresponding to the two flanks, from
the spine to the mammary chains including the shoulder and the thighs, no systemic effects are
observed.
Tolerance studies using 3 and 5 times the recommended dosage for twice the recommended duration
of treatment resulted in a reduced capacity for production of cortisol that is fully reversible within 7 to
9 weeks after the end of treatment.
Box containing a bottle.
17
For any information about this veterinary medicinal product, please contact the local representative of
the marketing authorisation holder.
België/Belgique/Belgien
VIRBAC BELGIUM S.A.
Rue de la station 17
B-1300 WAVRE
Tel: 32 (0) 10 47 06 35
Luxembourg/Luxemburg
VIRBAC BELGIUM S.A.
Rue de la station 17
B-1300 WAVRE
Tel: 32 (0) 10 47 06 35
Česká republika
VIRBAC S.A.
1 ère avenue 2065 m – L.I.D
F-06516 Carros
Tel: 33 (0) 4 92 08 73 00
Magyarország
VIRBAC S.A.
1 ère avenue 2065 m – L.I.D
F-06516 Carros
Tel: 33 (0) 4 92 08 73 00
Danmark
VIRBAC Danmark A/S
Profilvej 1
6000 Kolding
Tel: 45 75521244
Malta
VIRBAC S.A.
1 ère avenue 2065 m – L.I.D
F-06516 Carros
Tel: 33 (0) 4 92 08 73 00
Deutschland
VIRBAC Tierarzneimittel GmbH
West Rögen 20
D-23843 Bad Oldesloe
Tel: 49 (4531) 805 555
Nederland
VIRBAC NEDERLAND BV
Hermesweg 15
NL-3771 ND-Barneveld
Tel: 31 (0) 342 427 127
Eesti
OÜ ZOOVETVARU
Uusaru 5
ET - 76505 Saue/Harjumaa, ESTONIA
Tel: + 372 6 709 006
Norge
VIRBAC S.A.
1 ère avenue 2065 m – L.I.D
F-06516 Carros
Tel: 33 (0) 4 92 08 73 00
Ελλάδα
VIRBAC HELLAS A.E.
23 rd Klm National Road Athens-Lamia
145 65 Agios Stefanos
Athens
GREECE
Österreich
VIRBAC Österreich GmbH
Hildebrandgasse 27
A-1180 Wien
Tel: 43 (0) 1 21 834 260
España
VIRBAC ESPAŇA S.A.
C/Angel Guimera
179-181 – 08950 – Esplugues de Llobregat
E-Barcelona
Tel: + 34 93 470 79 40
Polska
VIRBAC S.A.
1 ère avenue 2065 m – L.I.D
F-06516 Carros
Tel: 33 (0) 4 92 08 73 00
France
VIRBAC S.A.
1 ère avenue 2065 m – L.I.D
F-06516 Carros
Tel: 33 (0) 4 92 08 73 00
Portugal
VIRBAC DE Portugal
LABORATÓRIOS LDA
P-2080 Almeirim
Tel: (351) 243 570 500
Ireland
C&M Veterinary Distributors Limited
IE-Limerick
Tel: 353 61 314 933
Slovenija
VIRBAC S.A.
1 ère avenue 2065 m – L.I.D
F-06516 Carros
Tel: 33 (0) 4 92 08 73 00
18
Ísland
VIRBAC S.A.
1 ère avenue 2065 m – L.I.D
F-06516 Carros
Tel: 33 (0) 4 92 08 73 00
Slovenská republika
VIRBAC S.A.
1 ère avenue 2065 m – L.I.D
F-06516 Carros
Tel: 33 (0) 4 92 08 73 00
Italia
VIRBAC SRL
Via dei Gracchi 30
I-20146 Milano
Tel: 39 02 48 53 541
Suomi/Finland
VIRBAC S.A.
1 ère avenue 2065 m – L.I.D
F-06516 Carros
Tel: 33 (0) 4 92 08 73 00
Κύπρος
GEO. PAVLIDES & ARAOUZOS LTD
25-27 Dimostheni Severi, 1080
CY-1080 Nicosia - CYPRUS
Τηλ: + 357 22456117
Sverige
VIRBAC S.A.
1 ère avenue 2065 m – L.I.D
F-06516 Carros
Tel: 33 (0) 4 92 08 73 00
Lietuva
OÜ ZOOVETVARU
Uusaru 5
ET - 76505 Saue/Harjumaa, ESTONIA
Tel: + 372 6 709 006
Република България
VIRBAC S.A.
1 ère avenue 2065 m – L.I.D
F-06516 Carros
Tel: 33 (0) 4 92 08 73 00
România
VIRBAC S.A.
1 ère avenue 2065 m – L.I.D
F-06516 Carros
Tel: 33 (0) 4 92 08 73 00
19
Latvija
OÜ ZOOVETVARU
Uusaru 5
ET - 76505 Saue/Harjumaa, ESTONIA
Tel: + 372 6 709 006
United Kingdom
VIRBAC Ltd
UK-Suffolk IP30 9 UP
Tel: 44 (0) 1359 243243


Source: European Medicines Agency



- Please bookmark this page (add it to your favorites).
- If you wish to link to this page, you can do so by referring to the URL address below this line.



http://www.theodora.com/drugs/eu/cortavance_veterinary.html

Copyright © 1995-2011 ITA all rights reserved.